C. Gleiter

Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer’s Mice
202127 citationsauthor #12
Cell motility and migration as determinants of stem cell efficacy
202033 citationsauthor #30
Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver
20209 citationsauthor #13
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats
201939 citationsauthor #11
A Risk Factor for Accidental Drug Overdose
20170 citationsauthor #3
Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trials.
201426 citationsauthor #6
Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease
2014141 citationsauthor #13
Integrating cancer patients' perspectives into treatment decisions and treatment evaluation using patient-reported outcomes--a concept paper.
201424 citationsauthor #4
Interplay between Endothelin and Erythropoietin in Astroglia: The Role in Protection against Hypoxia
201410 citationsauthor #6
Age-Dependent Astroglial Vulnerability to Hypoxia and Glutamate: The Role for Erythropoietin
201331 citationsauthor #9
Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model
20134 citationsauthor #13
Cell selection process and derived cells
20120 citationsauthor #4
No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine
201117 citationsauthor #2
Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
201117 citationsauthor #5
Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease
2011246 citationsauthor #18
Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.
20118 citationsauthor #2
Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis
201132 citationsauthor #6
Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease
2010153 citationsauthor #6
Pharmacokinetics of natural mistletoe lectins after subcutaneous injection
201026 citationsauthor #7
The Targeted Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions
200919 citationsauthor #7
' s response to reviews Title : Prediction of breast cancer by profiling of urinary RNA metabolites using SVM-based feature selection
20090 citationsauthor #8
Pairs of Creatine Kinase Serum Activity
20091 citationsauthor #7
MSc in clinical research – Danube University Krems
20090 citationsauthor #2
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
2009136 citationsauthor #6
Intranasal delivery of cells to the brain.
2009329 citationsauthor #12
Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection
200927 citationsauthor #8
Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin
200957 citationsauthor #19
Influence of Genetic Polymorphisms of VKORC1 and CYP2C9 in Patients on Phenprocoumon Steady-State Dose Requirements
20080 citationsauthor #7
Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients
200860 citationsauthor #6
Metabolic signature of breast cancer cell line MCF–7: Profiling of modified nucleosides via LC-IT MS coupling
20085 citationsauthor #5
Propafenone for the Prevention of Atrial Tachyarrhythmias After Cardiac Surgery: A Randomized, Double‐blind Placebo‐controlled Trial
200820 citationsauthor #21
Effect of Coadministered Ketoconazole, a Strong Cytochrome P450 3A4 Enzyme Inhibitor, on the Pharmacokinetics of Ciclesonide and its Active Metabolite Desisobutyryl-Ciclesonide
200814 citationsauthor #3
Penetration and accumulation of moxifloxacin in uterine tissue
20089 citationsauthor #6
Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients.
200826 citationsauthor #6
[Unwanted side effects of antibacterials--a diagnostic challenge].
20083 citationsauthor #3
Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis
200845 citationsauthor #7
Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer.
200849 citationsauthor #9
Pharmacokinetics of ML3403 ( -(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor
20070 citationsauthor #4
Angiotensin Receptor Type 1 Blockade in Astroglia Decreases Hypoxia-Induced Cell Damage and TNF Alpha Release
200727 citationsauthor #9
Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling
200749 citationsauthor #5
Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor
20070 citationsauthor #4
Psoriasis aggravation and metoprolol treatment -- a prospective observational case study.
20070 citationsauthor #6
Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor
200721 citationsauthor #4
Colocalization of glial fibrillary acidic protein, metallothionein, and MHC II in human, rat, NOD/SCID, and nude mouse skin keratinocytes and fibroblasts.
200738 citationsauthor #5
Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia.
200730 citationsauthor #9
Dose‐Proportional Intraindividual Single‐ and Repeated‐Dose Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor
200784 citationsauthor #10
Effect of High‐Dose Metronidazole on Pharmacokinetics of Oral Budesonide and Vice Versa: A Double Drug Interaction Study
200715 citationsauthor #5
In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS
200727 citationsauthor #6
Angiotensin receptor type 1 blockade in astrocytes decreases hypoxia-induced cytotoxicity and inflammation
20070 citationsauthor #7
Role of Renal Nerves and Salt Intake on Erythropoietin Secretion in Rats following Carbon Monoxide Exposure
20065 citationsauthor #8
Effect of endothelin-1 on erythropoietin production in a rat model under normoxia and functional carbon monoxide-induced hypoxia
20064 citationsauthor #9
Multiple drug prescribing by general practitioners in a German region: Implications for drug interactions and patient safety.
200616 citationsauthor #5
Common Neuroprotective Effects of Endothelin Receptor A Blockade and Erythropoietin During Hypoxia-Associated Cell Injury. Perspectives of Combined Treatment
20061 citationsauthor #3
St John's wort - an evidence based alternative for treatment of mood disorders in childhood and adolescence? Indications, efficacy and prescribing-patterns
20064 citationsauthor #4
Fenoterol: Pharmacology and Clinical Use
200616 citationsauthor #1
Theophylline Improves Early Allograft Function in Rat Kidney Transplantation
200613 citationsauthor #8
Quantitative determination of piritramide in human plasma and urine by off- and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry.
200617 citationsauthor #2
Adaptation of a high-performance liquid chromatographic method for quantitative determination of homocysteine in urine.
20059 citationsauthor #5
Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage).
200566 citationsauthor #2
Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC–ITMS coupling
200562 citationsauthor #5
Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity
20052 citationsauthor #1
lymphocytes in healthy male volunteers potential of erythrocytes and on DNA methylation of Effect of acute hyperhomocysteinemia on methylation
20050 citationsauthor #11
Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes
200514 citationsauthor #6
The blockade of endothelin A receptor protects astrocytes against hypoxic injury: common effects of BQ-123 anderythropoietin on the rejuvenation of the astrocyte population.
200513 citationsauthor #8
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study
2005131 citationsauthor #8
The Necessity of an Electronic SOP Retrieval System
20053 citationsauthor #4
MALDI-TOF MS analysis of urinary nucleosides
200564 citationsauthor #3
Similar protective effects of BQ-123 and erythropoietin on survival of neural cells and generation of neurons upon hypoxic injury.
200513 citationsauthor #8
Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial
2005117 citationsauthor #9
Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism.
200517 citationsauthor #5
HPLC-MS/MS analysis of willow bark extracts contained in pharmaceutical preparations.
200597 citationsauthor #4
Cyclooxygenase-2 Expression in Human Colorectal Cancer Is Unrelated to Overall Patient Survival
200569 citationsauthor #4
Transdermally applied scopolamine does not impair psychomotor performance
20045 citationsauthor #1
Ezetimibe and statin-associated myopathy.
200482 citationsauthor #5
Changes in caffeine seizure threshold after electroconvulsive shock
20042 citationsauthor #1
Effect of single and repeated electroconvulsive shock on the hypothalamic-pituitary-adrenal axis and plasma catecholamines in rats
200420 citationsauthor #2
Ginger-Associated Overanticoagulation by Phenprocoumon
200466 citationsauthor #5
Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species.
200416 citationsauthor #6
Does Angiotensin II Modulate Erythropoietin Production in HepG2 Cells?
200414 citationsauthor #4
Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects
200415 citationsauthor #6
Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
200478 citationsauthor #8
Anaphylaxis to intravenous sinistrin
200411 citationsauthor #5
Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L. (annual wormwood).
2004173 citationsauthor #4
A single electroconvulsive shock substantially lowers blood glucose levels in obese mice (C57BL/6J ob/ob)
20040 citationsauthor #1
Oral, Once-Daily Roflumilast and Its Active N-oxide Metabolite Exhibit Dose-Proportional Pharmacokinetics Between 250μg and 500μg
20043 citationsauthor #5
[Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
20041 citationsauthor #6
Repeated electroconvulsive shock increases the number of [3H]desipramine binding sites in rat cerebral cortex
20040 citationsauthor #1
Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry.
200416 citationsauthor #5
Repeated electroconvulsive shock does not change [3H]-paroxetine binding to the 5-HT uptake site in rat cortical membranes
20048 citationsauthor #1
Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: further evidence against a role for adenosine.
200311 citationsauthor #1
Arzneimittelinteraktionen
200313 citationsauthor #3
[Quality of antithrombotic therapy in patients with chronic atrial fibrillation: the AFib Trial].
20032 citationsauthor #8
Off-Label-Verordnungen in der Pädiatrie
20034 citationsauthor #3
[Phytotherapeutic medicines. A possible source of drug interactions].
20032 citationsauthor #2
Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo.
200322 citationsauthor #5
[Medicinal drugs and automobile driving ability].
20034 citationsauthor #2
Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine.
200320 citationsauthor #1
Letter to the editor concerning Ufer et al.: Eur J Clin Pharmacol 58:779–783 (2003)
20032 citationsauthor #1
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
20021,056 citationsauthor #16
Influence of controlled hypoxia and radical scavenging agents on erythropoietin and malondialdehyde concentrations in humans.
200231 citationsauthor #5

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT